Table 2 Median exposure per group (Cmin).

From: Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients

 

All patients

Adequate

Low

Total patients

167

56

111

PK samples total

1234

392

842

PK samples per patient

7 [4–11]

7 [3.8-9]

6 [4–11]

Median exposure (ng/mL)

16.5 [11.0–24.1]

20.8 [16.0–30.9]

14 [9.5–20.4]

Median exposure before intervention (ng/mL)

NA

NA

7.95 [5.65–13.0]*

Median exposure after intervention (ng/mL)

NA

NA

20.5 [14.3–34.0]*

  1. Data are expressed as number or as median [interquartile range]. *: only including patients who had an evaluable intervention (n = 86). Adequate: patients with all pharmacokinetic levels ≥8.4 ng/mL. Low: patients with ≥1 pharmacokinetic level <8.4 ng/mL.
  2. Cmin minimum plasma concentration at steady-state, PK pharmacokinetic, ng/mL nanogram per millilitre.